Congress quietly restores drug discounts for hospitals hit by Medicaid cuts
H.R. 10134 — Local Health Care Protection Act of 2026 · Filed by Hillary Scholten (D-MI) · Introduced Aug 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a temporary exception to the 340B drug discount program's eligibility rules for hospitals that lost their status due to Medicaid payment cuts. Hospitals that were enrolled on July 3, 2025, but no longer meet the disproportionate-share-hospital (DSH) threshold because of declining Medicaid reimbursements can continue accessing discounted drugs through 2030. The bill also requires a study of how Medicaid cuts affect rural hospital services and payment formulas.
Why we flagged it
The operative mechanism is a narrow eligibility waiver for a defined cohort of hospitals (those enrolled as of July 3, 2025) to restore access to 340B drug discounts. The study requirement is a secondary accountability measure addressing rural hospital decline, but the primary function is sectoral relief.
- GAO study of DSH criteria, rural payment decline, and alternative payment formulas is substantively unrelated to the eligibility waiver itself; it is a policy-research rider addressing broader Medicaid payment reform.
What the text implies
- The waiver is time-limited (through Sept 30, 2030) but applies retroactively to cost-reporting periods beginning in FY 2026, creating a window where hospitals can recapture discounts they lost mid-fiscal-year due to Medicaid cuts.
- The bill does not require hospitals to pass drug-cost savings to patients, uninsured populations, or charity care; savings may accrue to hospital balance sheets or executive compensation.
The full analysis lists 5 implications of this text.
Who stands to gain
hospitals (nonprofit and for-profit); hospital systems; rural health networks